EU Crunch Time For Bluebird’s Neurodegenerative Disorder Gene Therapy
US Filing Expected Mid-2021
The EU could become the first market in which eli-cel is approved if the gene therapy for cerebral adrenoleukodystrophy this week passes muster with the European Medicines Agency.
